Skin Cancer Screening
CATCHING IT EARLY
EVERY SIX MONTHS
In over 25 years, not one person in the program has died from skin cancer or even had a close call:
The Skin Check Program – 1992 to Present
But NO DEATHS due to any skin cancers
Full skin examinations, if performed in a serial manner, ideally every 6 to 12 months, by dermatologists or other medical personnel who have been specifically trained for this procedure, can result in cures of skin cancer in almost all cases. We recommend such examinations for individuals with a history of significant past sun or ultraviolet light exposure (e.g. tanning salons), particularly if there have been severe or blistering sunburns at any time in the past, since this predisposes to melanoma in particular. In addition, we recommend these examinations for individuals with the following additional risk factors.
Fair skin types.
Red or blond hair.
Past history of any skin cancer.
Family history of melanoma.
Although not widely known by the public at this time, light skinned men over 50 are particularly at risk for both developing and dying of melanoma. We highly recommend that such individuals, particularly those with a history of multiple and/or severe sunburns, participate in serial screening programs. Doing so could be life-saving.
Get the latest updates on our research.
Delivering Cures for Cancer
4701 Randolph Rd.
Rockville MD 20852
*All donations are tax deductible.
OR DONATE ONLINE
support us and changethe future of cancer.
Drs. Ronald Shore and Joseph Fox, who founded Delivering Cures for Cancer and The Paula Shore/Sari Fox Foundation, receive no salary, income or other compensation from the Foundation. Their donations have covered the majority of the start up costs including website, legal, accounting, administrative, and promotions expenses. Dr. Shore, whose skin cancer screening program is described on this website, has helped to educate fellow dermatologists and other medical personnel on how to perform highly effective skin cancer screening through international lectures and publications, largely at personal expense. Honoraria for his presentations, if provided, have been returned to the institution (e.g. University of Pennsylvania), or given to charity (e.g. The Society for Dermatologic Physician Assistants). He receives no other compensation from industry, academic institutions or other entities. Dr. Shore has volunteered his time and knowledge on screening to 20/20 GeneSystems, Inc., the developer of the PAULAs Test, a new blood test for early detection of lung cancer. He has also served on its Medical Advisory Board. He has received no remuneration for these forms of assistance. Dr. Shore and Dr. Fox were each approached by 20/20 GeneSystems, Inc. to purchase shares to help the company continue its research, and both agreed to do so. Their investments in the company, in each case, represent well under 1% of total investments. Neither physician holds any controlling or voting position in the company, nor draws any salary or other compensation. Dr. Shore and Dr. Fox, who for several years have spoken to various individuals, organizations and government personnel to try to advance Dr. Esther Chang’s research, were each approached by SynerGeneTherape